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Background. Published data on the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in persons aged ≥65 years are limited. This study aims to examine a large cohort of Tdap users ≥65 years for evidence of increased risk of adverse events following vaccination.
Methods. A matched cohort study design and a self-controlled case series (SCCS) design were used. The study population was adults aged ≥65 years who received the Tdap or tetanus and diphtheria (Td) vaccine during 1 January 2006-31 December 2010 at 7 health maintenance organizations in the United States. Seven major groups of prespecified events were identified electronically by diagnostic codes.
Results. The study included 119 573 Tdap vaccinees and the same number of Td vaccinees. The results indicated that the risk of the prespecified events following Tdap was comparable to that following Td vaccination in this elderly population. There was a small increased rate of codes suggesting medically attended inflammatory or allergic events in 1-6 days following Tdap in the SCCS analysis (incidence rate ratio, 1.59 [95% confidence interval, 1.40-1.81]).
Conclusion. Although there is a small increased risk of medically attended inflammatory or allergic events in 1-6 days following Tdap compared to other time periods, it is no more common than that following Td. This study provides empirical safety data suggesting that immunizing adults aged ≥65 years with Tdap to reduce the risk of pertussis in the elderly and their contacts should not have untoward safety consequences.
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Pertussis is highly contagious and is spread by inhalation of respiratory droplets or aerosols. A high population level of immunity is needed to reduce the incidence of pertussis in the community, but immunity from immunization wanes over time. [1] Pertussis continues to circulate widely and can lead to the infection, hospitalization, and death of young infants who are too young for routine immunization with pertussis vaccine. The most common known source of pertussis in infants is parents (55%), with siblings and other relatives making up most of the remainder (32%) [2] .
Two tetanus-diphtheria-acellular pertussis (Tdap) vaccines were licensed for use in the United States in spring 2005. One was licensed for use in children and adolescents aged 10-18 years (Boostrix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and another was for use in children/adolescents and adults aged 11-64 years (Adacel, Sanofi Pasteur, Toronto, Canada). In 2008, Boostrix was licensed for use in an expanded age range in persons aged 10-64 years. It was not licensed for use in persons aged ≥65 years until July 2011.
Since the 1980s, the number of reported pertussis cases has increased, paralleled by an increase in the number of reported deaths from pertussis among very young infants [3] . The 2010 outbreak in California is a reminder of how serious pertussis infections are and the importance of pertussis immunization [4] . In 2006, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescents and adults receive a one-time dose of Tdap [5, 6] . In 2010, the ACIP recommended that for adults aged ≥65 years, a single dose of Tdap may be administered instead of Td (tetanus and reduced diphtheria toxoid) vaccine if they previously had not received Tdap [7] .
Published data on the safety of Tdap in persons aged ≥65 years are limited as this population was not included in prelicensure studies and the vaccine was initially not licensed for this age group. As the number of elderly individuals receiving Tdap increases, evaluation of the safety of the vaccine in this population becomes essential. This study aims to examine a large cohort of off-label Tdap users aged ≥65 years for evidence of any increased risk of adverse events following vaccination, using the matched cohort design and the selfcontrolled case series (SCCS) method [8] [9] [10] .
METHODS
Two hypotheses were tested in the study: (1) in persons aged ≥65 years, prespecified adverse events were no more common following Tdap than in a matched population that received Td; (2) in persons aged ≥65 years, prespecified adverse events were no more common after Tdap vaccination than in a comparison period. Two study designs were used to examine these hypotheses: a cohort study design using a matched population who received Td during the same time period, and an SCCS design.
Study Population
Matched Cohort Design The exposed cohort was comprised of adults aged ≥65 years who received the Tdap vaccine during 1 January 2006-31 December 2010 and had at least 1 year of continuous membership before vaccination until 84 days after vaccination at 7 US managed care organizations participating in the Vaccine Safety Datalink (VSD) Project [11] . The continuous membership requirement was applied to increase the likelihood of identifying only incident adverse events and also to ensure that the same exposed population was used for all adverse events in 2 study designs.
The unexposed cohort, vaccinated with a Td vaccine during the same period with the same membership requirement, was 1:1 matched to the exposed group by age group (65-69, 70-74, ≥75), sex, site, and season (April-October, NovemberMarch). Vaccination year was not included as a matching variable because Tdap has been the dominant tetanus and pertussis-containing vaccine given to subjects of this age group at the 2 California sites since the recommendation by the California Department of Public Health [12] . As a result, the comparison of a concurrent matched Td population was not practical at these sites.
Self-Controlled Case Series Design
An SCCS analysis was performed in the exposed cohort of the matched cohort study only. For each adverse event, the incidence in the postvaccination risk period was compared with that in a comparison period, which started the day after the condition-specific risk period and lasted the same length of time.
Prespecified Adverse Events
Prespecified events that had been studied in other VSD studies of Tdap in adolescent and adult populations were included [13, 14] . Events of interest were identified by diagnoses that were coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Seven major groups of adverse events were evaluated, including meningitis, encephalitis, and encephalopathy; cranial nerve disorders, including Bell's palsy; Guillain-Barré syndrome (GBS); brachial neuritis; paralytic syndromes; medically attended inflammatory or allergic events; and "anaphylaxis and generalized reaction" (Table 1) . Encephalitis, encephalopathy, GBS, and Bell's palsy were included because the 2011 Institute of Medicine (IOM) report concluded that the evidence is inadequate to accept or reject a causal relationship between them and vaccination with diphtheria toxoid-, tetanus toxoid-, or acellular pertussis-containing vaccines due to insufficient epidemiologic or mechanistic evidence [15] . In the 1993 IOM report, the committee found that the evidence favored acceptance of a causal relation between vaccination with diphtheria and tetanus toxoid-containing vaccines and GBS and brachial neuritis [16] . Unilateral facial paralysis and nerve compression were reported following Tdap vaccination during clinical trials conducted in individuals aged 11-64 years [17, 18] . Medically attended inflammatory or allergic events and anaphylaxis and generalized reaction were included based on reports to the Vaccine Adverse Event Reporting System (VAERS) and safety data from clinical trials in younger populations [17] [18] [19] . The IOM report concluded that the evidence convincingly supports a causal relationship between tetanus toxoid-containing vaccine and anaphylaxis. However, the evidence was inadequate to accept or reject a causal relationship between diphtheria toxoid or acellular pertussis vaccines and anaphylaxis. [15] Computerized data were used to search for the prespecified adverse events. To avoid preexisting diagnoses (ie, visits for follow-up of an existing condition), all diagnostic codes were the first event documented within the previous year or previous 30 days for that individual (Table 1) . Medical records were reviewed to confirm the diagnosis if an increased risk was found by either design. Information being reviewed included onset date, cause of the condition, and description of reaction. The length of the risk window for the prespecified adverse events varied from 6 to 42 days, depending on the event of interest. Shorter windows were chosen for medically attended inflammatory or allergic events and for anaphylaxis and generalized reaction because of their immediate onset. All events diagnosed on the day of vaccination (day 0) except for anaphylaxis and generalized reaction were excluded to eliminate events with onset prior to vaccination.
Statistical Analysis
In the matched cohort design, the odds ratio (OR) and 95% confidence interval (CI) of each adverse event comparing the Tdap exposed group and the matched unexposed cohort were estimated by logistic regression. This was done with and without adjustment for vaccination year. In the SCCS design, only participants with an event of interest occurring after vaccination were included. The incidence rate of an event of interest in the risk window was compared with that in a comparison window by conditional Poisson regression. We assumed that age and calendar time were not time-varying confounders since the observational period was relatively short and the risk of events of interest was not likely to vary significantly over the short period of time.
It is possible that visits could increase shortly after a wound, trauma, or animal bite. If Td was given more commonly than Tdap for these conditions, one would expect a biased comparison for visits following them. ICD-9-CM codes suggesting medically attended inflammatory or allergic events like 682.3, 682.8, 682.9 (cellulitis), 729.5 (pain in limb), and 729.81 (limb swelling) would be the ones that are most likely affected. Therefore, we also performed a sensitivity analysis by excluding Td or Tdap given on the day when there was an emergency department visit with codes for wound/trauma or animal bite.
The power calculation was based on the matched cohort design. Assuming the incidence of an adverse event was 0.01% in the unexposed group and OR was 2.5 comparing the exposed group with the unexposed group, with a predetermined limit for type I error of 5%, the power of rejecting the null hypothesis for a 1:1 matched cohort study of our size could reach 79.3%. All analyses were conducted using SAS Enterprise Guide 4.2 (SAS Institute Inc, Cary, North Carolina). The institutional review boards of each participating organization approved this study. Table 2 reports the OR and 95% CI estimates of adverse events comparing the Tdap-and Td-vaccinated cohorts. There was no increased risk of meningitis, encephalitis, encephalopathy, cranial nerve disorders, GBS, brachial neuritis, paralytic syndromes, and medically attended inflammatory or allergic events comparing the Tdap vaccinees with the Td vaccinees.
There was a >3-fold increased risk of anaphylaxis and generalized reaction diagnoses following Tdap immunization (adjusted OR, 3.72 [95% CI, 1.54-8.94]). Because of this possible increased risk, we reviewed medical records of these events. Our medical record review indicated that there was no case of anaphylaxis following either Tdap or Td, and only 2 patients in the Tdap group and 1 patient in the Td group had a generalized reaction that was related to these vaccines. The patient in the Td group and one of the patients in the Tdap group also received concomitant pneumococcal vaccine. Both had "fever" as the reported generalized reaction. The one patient who received only Tdap had "erythematous, blanching confluent smooth rash over right and left breast, abdomen, and inside of thighs." This patient "vaguely recalled having a similar reaction to Tdap vaccination in the past." The unadjusted OR was 2.00 (95% CI, .10-118.00) after excluding all but these 3 cases based on the medical record review, whereas the adjusted OR was not estimable owing to small numbers. Eight cases in the Tdap group and 4 cases in the Td group had mild, self-limiting local reactions. Ten cases in the Tdap group and 3 cases in the Td group were non-Tdap/Td-related conditions, had no reaction, or were associated with a preexisting diagnosis. The specifics of 2 cases in the Tdap group and 1 case in the Td group were unclear (limited information available in the medical record or unknown cause). Table 3 presents the results of the self-controlled case series design, comparing the incidence of prespecified adverse events in the risk window to that in the comparison window. There was no increased risk of meningitis, encephalitis, encephalopathy, cranial nerve disorders, GBS, brachial neuritis, or paralytic syndromes in the risk window. The incidence rate ratio of medically attended inflammatory or allergic events was 1.59 (95% CI, 1.40-1.81). There was a >7-fold increased incidence of anaphylaxis and generalized reaction in the risk window based on the automated cases. SCCS analysis of this event using medical record reviewed cases was not performed. Because the causes of anaphylaxis and generalized reaction were determined during the medical record review process and a reaction attributed to vaccination was, by definition, more likely to occur in the period right after vaccination (the risk window), the relative risk estimated by the SCCS design would be inevitably biased.
The sensitivity analysis excluded 4396 (3.7%) Td vaccinees and 2434 (2.0%) Tdap vaccinees who received the vaccine on the day when there was an emergency department visit for a wound/trauma or animal bite. The results were not affected and the estimates of relative risk were similar to the results of the original analyses.
DISCUSSION
In this study, we evaluated the safety of Tdap given off-label to adults aged ≥65 years. Two approaches to examine the safety profile were used. First, a matched cohort study design was used to examine whether the incidences of selected adverse events in the risk window following Tdap vaccination was higher than that following Td vaccination. Second, we used the SCCS design to evaluate whether the risks of selected adverse events were higher in the prespecified risk window following Tdap vaccination than in the comparison window. In the matched cohort analyses, we found an elevated risk of anaphylaxis and generalized reaction comparing Tdap vaccination with Td based on diagnostic codes. However, after reviewing the medical records, there were only 2 mild cases of fever and rashes following Tdap. The risk of medically attended inflammatory or allergic events was comparable between Tdap and Td. In the SCCS analyses, the risk of medically attended inflammatory or allergic events was higher in the prespecified risk window following Tdap vaccination than that in the comparison window. The increased risk of medically attended inflammatory or allergic events following Tdap is consistent with the VAERS reports and data from clinical trials in younger populations [17] [18] [19] . Moro et al [19] reviewed the VAERS Tdap reports during 2005-2010 in adults aged ≥65 years. More than half of the 243 reports indicated local reactions of erythema (25.1%), pain (15.6%), and/or swelling (13.6%) at the injection site. Severe pain was noted in 2 reports. Systemic reactions (eg, fever, chills, and malaise) were reported less frequently. About one-third of the total 243 reports indicated an inappropriate schedule of drug administration or medication error. These reports reflected the fact that the vaccine was, in fact, used offlabel during that period. Eleven serious events were reported, including 2 deaths considered unlikely to be related to vaccine receipt among persons with multiple underlying conditions. The authors concluded that the safety profile of Tdap is similar to that of Td, which has a good history of safety in older persons [20] .
Our data corroborate this conclusion and suggest that the magnitude of increased risk of medically attended inflammatory or allergic events following Tdap seems comparable to that following Td. The relative risk estimated by the SCCS design provides an estimate of 1.6-fold increased risk following Tdap in the prespecified risk window than in the comparison window. As injection site reactions are common and expected following Tdap vaccination [15, 17, 18] , our finding of an increased risk of medically attended inflammatory or allergic events provides a validation of the data. One potential bias is that by including ICD-9 codes 995.2 (other and unspecified adverse effect of drug, medicinal and biological substance), 999.3 (infection, sepsis, septicemia following infusion, injection, transfusion, or vaccination), and 999.9 (complications of medical care, not elsewhere classified), one would expect, by definition, more events being captured in the period following a vaccination than in the comparison period. If the 3 codes were removed (74 cases in the risk window and 22 in the control window), the rate ratio would be 1.48 (95% CI, 1.30-1.69).
The safety profile of Tdap in the elderly population ≥65 years of age in this study is comparable to that in the younger population. The safety of Tdap vaccine was monitored weekly among VSD subjects aged 10-64 years during 2005-2008 as a rapid cycle analysis study [14] . The following 5 categories of potential adverse events were monitored: encephalopathyencephalitis-meningitis; paralytic syndromes; seizure; cranial nerve disorders, including Bell's palsy; and GBS. No evidence of an association was found between Tdap and any of the 5 predefined adverse events in a surveillance period that included 660 245 doses of Tdap over the course of 145 weeks. Similarly, we found there was no increased risk of serious adverse events following Tdap, either compared with the risk following Td or with the risk in a self-comparison period.
In 2006, ACIP recommended an interval of at least 5 years between Tdap and the last tetanus-or diphtheria-containing vaccines because of concern about increased local reactogenicity after Tdap vaccinations [5] . In 2010, the ACIP supported removal of the interval language and stated that Tdap can be administered regardless of interval since the last tetanus-or diphtheria-containing vaccines [7] In our study, we have the opportunity to compare the incidence of medically attended inflammatory or allergic events between 18 069 Tdap vaccinees who had a history of tetanus-or diphtheria-containing vaccines within 5 years of Tdap vaccination and 101 504 Tdap vaccinees who had no such history. The OR was 0.92 (95% CI, .72-1.16). Our data suggest no increased risk of reactogenicity following Tdap if there was a history of receiving tetanus-or diphtheria-containing vaccines within 5 years. Although there is the possibility that we had a selected sample of lower-risk groups who did not experience severe local or systemic reactions after their previous tetanus-or diphtheria-containing vaccination, we expect the number of severe events to be minimal. Other studies have demonstrated the safety of giving a single dose of Tdap at a shorter interval after tetanusdiphtheria or tetanus toxoid vaccine in children or young adults [21] [22] [23] . Our results are in line with the recommendation that history of Td vaccination should not deter one from administering the combined vaccine that also protects against pertussis.
While these results are reassuring, there are several potential limitations that should be considered. One potential limitation of our study is that the adverse events under investigation were prespecified on the basis of previously published studies and VAERS reports for Tdap and similar vaccines. Unexpected outcomes were not studied. Another potential limitation is the misclassification of exposure and event status because the study relied primarily on electronic medical record data. Medical record reviews were conducted only when there was statistically significant increased risk. False-negative results might potentially have been overlooked.
In summary, the results suggest that the risk of the prespecified events following Tdap is comparable to that following Td vaccination in the elderly population. Although there is a small increased risk of medically attended inflammatory or allergic events in 1-6 days following Tdap compared to other time periods, it is no more common than that following Td.
